Zentalis Pharmaceuticals Inc
ZNTL1.390USD
+0.050+3.73%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
100.01MValor de mercado
PerdaP/L TTM
Mais detalhes de Zentalis Pharmaceuticals Inc Empresa
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Informações da empresa
Código da empresaZNTL
Nome da EmpresaZentalis Pharmaceuticals Inc
Data de listagemApr 03, 2020
CEOMs. Julie Eastland
Número de funcionários166
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 03
Endereço10275 Science Center Drive
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92121
Telefone18582634333
Sitehttps://www.zentalis.com/
Código da empresaZNTL
Data de listagemApr 03, 2020
CEOMs. Julie Eastland
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Ms. Andrea Paul, J.D.
Ms. Andrea Paul, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.98K
-96.55%
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
Mr. Scott Myers
Mr. Scott Myers
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Julie Eastland
Ms. Julie Eastland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Ms. Andrea Paul, J.D.
Ms. Andrea Paul, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.98K
-96.55%
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2019
FY2018
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 23 de jul
Atualizado em: qua, 23 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Matrix Capital Management Company, LP
19.40%
Walters (William T)
9.80%
BlackRock Institutional Trust Company, N.A.
5.33%
The Vanguard Group, Inc.
4.53%
Millennium Management LLC
4.27%
Other
56.67%
Investidores
Investidores
Proporção
Matrix Capital Management Company, LP
19.40%
Walters (William T)
9.80%
BlackRock Institutional Trust Company, N.A.
5.33%
The Vanguard Group, Inc.
4.53%
Millennium Management LLC
4.27%
Other
56.67%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
33.53%
Investment Advisor
20.08%
Hedge Fund
18.52%
Individual Investor
12.74%
Research Firm
4.62%
Venture Capital
3.66%
Corporation
1.33%
Endowment Fund
0.24%
Family Office
0.13%
Other
5.14%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
373
68.31M
94.93%
-22.23M
2025Q1
386
70.02M
97.36%
-19.46M
2024Q4
379
71.39M
100.17%
-15.78M
2024Q3
373
74.19M
104.47%
-21.21M
2024Q2
365
79.92M
112.67%
-23.64M
2024Q1
360
88.75M
125.22%
-9.75M
2023Q4
361
83.47M
118.17%
-13.77M
2023Q3
361
82.76M
117.68%
-11.58M
2023Q2
361
84.96M
121.10%
+6.07M
2023Q1
342
70.12M
118.05%
-6.08M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Matrix Capital Management Company, LP
13.96M
19.4%
--
--
Mar 31, 2025
Walters (William T)
7.05M
9.8%
+3.05M
+76.25%
Jan 29, 2025
BlackRock Institutional Trust Company, N.A.
3.83M
5.33%
-10.27K
-0.27%
Mar 31, 2025
The Vanguard Group, Inc.
3.26M
4.53%
-10.63K
-0.32%
Mar 31, 2025
Millennium Management LLC
3.07M
4.27%
-711.78K
-18.82%
Mar 31, 2025
Acadian Asset Management LLC
2.67M
3.72%
+1.61M
+150.56%
Mar 31, 2025
Decheng Capital LLC
2.02M
2.81%
-318.33K
-13.62%
Mar 31, 2025
Opaleye Management Inc.
1.99M
2.76%
+217.50K
+12.31%
Mar 31, 2025
Almitas Capital LLC
1.71M
2.38%
+84.03K
+5.16%
Mar 31, 2025
Tang Capital Management, LLC
1.50M
2.08%
+1.50M
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Federated Hermes MDT Small Cap Core ETF
0.07%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity Growth Opportunities ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Ver Mais
Federated Hermes MDT Small Cap Core ETF
Proporção0.07%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.01%
iShares Micro-Cap ETF
Proporção0.01%
Fidelity Enhanced Small Cap ETF
Proporção0.01%
Invesco Nasdaq Biotechnology ETF
Proporção0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0%
Fidelity Growth Opportunities ETF
Proporção0%
T Rowe Price Small-Mid Cap ETF
Proporção0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0%
ProShares Ultra Nasdaq Biotechnology
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
